

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Kaneh Bosm BioTechnology Inc. (the “**Issuer**”)
Suite 800– 1199 West Hastings Street
Vancouver, BC V6E 3T5

Item 2 Date of Material Change

April 27, 2018

Item 3 News Release

The news release was disseminated on April 27, 2018 by way of the facilities of Stockwatch and Market News Publishing Inc. Copies were also filed on SEDAR with the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.

Item 4 Summary of Material Change

The Company announced that Mr. Eugene Beukman has been appointed to the Issuer’s board of directors. The appointment follows the resignations of Mr. Matthew Lechtzier as a director.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

Please see the attached news release dated April 27, 2018.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted:

Rudy de Jonge, Chief Executive Officer and Director

Business Telephone: 604-782-4191

Item 9 Date of Report

April 27, 2018

Kaneh Bosm BioTechnology Inc.
800 – 1199 West Hastings Street
Vancouver BC V6E 3T5
Tel: 604.782.4191

NOT FOR DISSEMINATION IN THE UNITED STATES

NEWS RELEASE

**April 27, 2018 – Vancouver, B.C. - - Kaneh Bosm BioTechnology Inc. (the “Company”) (CSE: KBB)
Appoints Eugene Beukman to the board of directors**

Kaneh Bosm BioTechnolgy Inc. (KBB:CSE) (“Kaneh Bosm” or the “Company”) is pleased to announce the appointment of Mr. Eugene Beukman to its board of directors.

Eugene Beukman is the Corporate Counsel of the Pender Group of Companies, a position he has held since January 1994. He graduated from the Rand University of Johannesburg, South Africa with a Bachelor of Law degree and a Bachelor of Law Honors Postgraduate degree in 1987. After practicing as a lawyer, Mr. Beukman was employed as a legal advisor to the BHP Billiton group companies. He has over thirty years' experience in the acquisition of assets and joint ventures. He is an advocate of the High Court of South Africa and serves as CEO and Director on a number of TSX Venture Exchange and CSE listed companies.

The appointment follows the resignations of Mr. Matthew Lechtzier as a director. Kaneh Bosm would like to thank Matthew for his many years of service to the Company and wishes him well with his future endeavors.

On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

“Rudy de Jonge”

Rudy de Jonge
CEO, Director
rudydejonge@hotmail.com
(604) 782-4191

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking

statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com